[go: up one dir, main page]

MX2016004328A - Inmunopotenciador. - Google Patents

Inmunopotenciador.

Info

Publication number
MX2016004328A
MX2016004328A MX2016004328A MX2016004328A MX2016004328A MX 2016004328 A MX2016004328 A MX 2016004328A MX 2016004328 A MX2016004328 A MX 2016004328A MX 2016004328 A MX2016004328 A MX 2016004328A MX 2016004328 A MX2016004328 A MX 2016004328A
Authority
MX
Mexico
Prior art keywords
glucan
immunopotentiator
immunopotencer
poly
modified
Prior art date
Application number
MX2016004328A
Other languages
English (en)
Other versions
MX386144B (es
Inventor
Yoichiro Koshi
Joonsik Park
Jiao Lu
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2016004328A publication Critical patent/MX2016004328A/es
Publication of MX386144B publication Critical patent/MX386144B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

Se proporciona un inmunopotenciador que comprende, como un ingrediente activo, un ß-glucano modificado el cual ß-glucano y el poli (ácido hidroxi) se unen covalentemente. El inmunopotenciador puede mejorar fuertemente la acción de inmunopotenciación del ß-glucano.
MX2016004328A 2013-10-09 2014-10-09 Inmunopotenciador. MX386144B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013212103 2013-10-09
PCT/JP2014/077038 WO2015053354A1 (ja) 2013-10-09 2014-10-09 免疫賦活化剤

Publications (2)

Publication Number Publication Date
MX2016004328A true MX2016004328A (es) 2016-07-11
MX386144B MX386144B (es) 2025-03-18

Family

ID=52813169

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004328A MX386144B (es) 2013-10-09 2014-10-09 Inmunopotenciador.

Country Status (14)

Country Link
US (1) US10556004B2 (es)
EP (1) EP3056208B1 (es)
JP (1) JP6146676B2 (es)
KR (1) KR102343005B1 (es)
CN (1) CN105611936B (es)
AU (1) AU2014332835B2 (es)
BR (1) BR112016007130B1 (es)
CA (1) CA2926720A1 (es)
DK (1) DK3056208T3 (es)
ES (1) ES2887367T3 (es)
MX (1) MX386144B (es)
PL (1) PL3056208T3 (es)
RU (1) RU2702987C2 (es)
WO (1) WO2015053354A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110237249A (zh) * 2018-03-09 2019-09-17 南开大学 特异靶向树突状细胞的新型铝佐剂及在疫苗制备上的应用
TWI862656B (zh) * 2019-08-09 2024-11-21 日商三菱商事生命科學股份有限公司 生活習慣病預防或改善用組成物
CA3230661A1 (en) 2021-08-30 2023-03-09 Toray Industries, Inc. Composition for enhancing immunogenicity
CN117813112A (zh) 2021-08-30 2024-04-02 东丽株式会社 免疫原性增强用组合物
KR20240065074A (ko) 2021-09-16 2024-05-14 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3871892A (en) * 1972-12-18 1975-03-18 Hayashibara Biochem Lab Shaped bodies of pullulan esters and their use
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
EP0640348A1 (en) 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
JP4091136B2 (ja) * 1997-01-17 2008-05-28 キリンフードテック株式会社 免疫賦活剤
US20040057958A1 (en) 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
US20050272694A1 (en) 2003-03-07 2005-12-08 Aureo Co., Ltd Composition containing beta-glucan and constipation-relieving drug, immunopotentiatior, and skin moistening agent using the composition
JP5138954B2 (ja) 2006-03-09 2013-02-06 独立行政法人科学技術振興機構 両親媒性高分子複合体
JP6082174B2 (ja) 2006-11-06 2017-02-15 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 免疫調節組成物及びその使用方法
EP2224933B1 (en) * 2007-11-26 2016-08-03 GlaxoSmithKline Biologicals SA Conjugated beta-1,3-linked glucans
US20100266626A1 (en) 2007-11-26 2010-10-21 Francesco Berti Adjuvanted glucans
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
US8431161B2 (en) * 2008-02-22 2013-04-30 Toray Industries, Inc. Microparticle and pharmaceutical composition thereof
JP5429707B2 (ja) * 2008-03-27 2014-02-26 国立大学法人群馬大学 微粒子およびその製造方法
EP2402032B1 (en) * 2009-02-27 2019-08-14 Toray Industries, Inc. Immunogenic composition
ES2829819T3 (es) * 2010-08-26 2021-06-02 Toray Industries Composición inmunogénica
GB201020193D0 (en) * 2010-11-29 2011-01-12 Biotec Pharmacon Asa Glucan compositions
JP2013067709A (ja) 2011-09-21 2013-04-18 Gunze Ltd ヒアルロン酸修飾物

Also Published As

Publication number Publication date
MX386144B (es) 2025-03-18
CA2926720A1 (en) 2015-04-16
KR102343005B1 (ko) 2021-12-24
DK3056208T3 (en) 2021-11-15
WO2015053354A1 (ja) 2015-04-16
BR112016007130B1 (pt) 2023-01-31
BR112016007130A2 (pt) 2020-06-16
US20160256543A1 (en) 2016-09-08
AU2014332835B2 (en) 2019-07-25
JPWO2015053354A1 (ja) 2017-03-09
EP3056208B1 (en) 2021-08-18
JP6146676B2 (ja) 2017-06-14
CN105611936B (zh) 2021-08-20
KR20160060072A (ko) 2016-05-27
RU2702987C2 (ru) 2019-10-15
RU2016116786A (ru) 2017-11-15
AU2014332835A1 (en) 2016-04-28
RU2016116786A3 (es) 2018-08-01
ES2887367T3 (es) 2021-12-22
EP3056208A1 (en) 2016-08-17
EP3056208A4 (en) 2017-06-14
CN105611936A (zh) 2016-05-25
PL3056208T3 (pl) 2021-12-20
US10556004B2 (en) 2020-02-11

Similar Documents

Publication Publication Date Title
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
CR20170100A (es) Indazoles sustituidos con bencilo como inhibidores bub1
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
PH12016500720A1 (en) Stable formulation of insulin glulisine
MX375378B (es) Formulaciones de anticuerpos anti-pdl1.
EA201591340A1 (ru) Модулятор андрогенного рецептора и его применения
MX2016008448A (es) Conjugados de var2csa-farmaco.
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
TWD178856S (zh) 電連接器
BR112017018620A2 (pt) método de administração de tradipitanto, e, tradipitanto.
MX373309B (es) Composiciones antibióticas de ceftolozano.
MX2015011837A (es) Co-cristale de pirimetanil y tetracarboximida de ditiina seleccionada.
UA115373C2 (uk) Стабільний рідкий склад amg 416 (велкалсетиду)
MX2016004328A (es) Inmunopotenciador.
BR112016015394A8 (pt) sistemas de geração de pulso elétrico
TWD182977S (zh) 卡連接器
MX371128B (es) Compuestos de dihidropirimidin-2-ona y su uso medico.
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
MX2018005085A (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos de fabricacion y uso de las mismas.
MX368268B (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
TWD182979S (zh) 卡連接器
TR201819130T4 (tr) Sulu Formülasyonlar, Bunların Üretimi Ve Kullanımı
TWD182980S (zh) 卡連接器
TWD182978S (zh) 卡連接器
UA90039U (en) Ethyl ester of 6-thioxo-3-(4-fluorophenyl)-7-cyano-1,3,4,6-2h-pyrido[1,2-a][1,3,5]triazine-9-carboxylic acid